Skip to main content
SpringerLink
Log in

Plans for Human Trials of a Vaccine Against Epstein-Barr Virus Infection

  • Chapter
Medical Virology 9

  • 150 Accesses

Abstract

Evidence linking Epstein-Barr (EB) virus to two human cancers, endemic Burkitt’s lymphoma (BL) (Burkitt, 1963) and undifferentiated nasopharyngeal carcinoma (NPC) (Shanmugaratnam, 1971), has accumulated steadily over the years (Epstein and Morgan, 1983; Lenoir and Bornkamm, 1987; Whittle et al. 1984). Already in 1976 enough was known for it to be evident that EB virus was an essential link in a complicated chain of events leading inexorably to the malignant tumors, and it therefore seemed reasonable to suppose that if infection by the virus could be prevented, the incidence of these tumors in populations at risk would be decreased (Epstein, 1976). In view of the compelling analogy afforded by the effect of avoiding cigarette smoking on the incidence of bronchogenic carcinoma (Doll and Peto, 1976), it seemed unethical not, at least, to explore the possibility of vaccine intervention to prevent EB virus infection in the context of BL and NPC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Allison AC, Byars NE (1986) An adjuvant formulation that selectively elicits the formation of antibodies of protective isotype and cell mediated immunity. J Immunol Methods 95:157–168.

    Article  PubMed  CAS  Google Scholar 

  • Allison AC, Byars NE (1987) Vaccine technology: adjuvants for increased efficiency. Biotech 5:1041–1045.

    Article  CAS  Google Scholar 

  • Beisel C, Tanner J, Matsuo T, Thorley-Lawson D, Kezdy F, Keiff E (1985) Two major outer envelope glycoproteins of Epstein-Barr virus encoded by the same gene. J Virol 54:665–674.

    PubMed  CAS  Google Scholar 

  • Biggin M, Farrell PJ, Barrell BG (1984) Transcription and DNA sequence of Gam HIL fragment of B95-8 Epstein-Barr virus. EMBO J 3:1083–1090.

    PubMed  CAS  Google Scholar 

  • Burkitt D (1963) A lymphoma syndrome in tropical Africa. In Richter GW, Epstein MA (eds) International Review of Experimental Pathology. New York, London. Academic Press, Inc, pp. 67–138.

    Google Scholar 

  • Cammoun M, Hoerner GV, Mourali N (1974) Tumors of the nasopharynx in Tunisia: an anatomic and clinical study based on 143 cases. Cancer 33:184–192.

    Article  PubMed  CAS  Google Scholar 

  • Churchill AE, Payne LN, Chubb RC (1969) Immunization against Marek’s disease using a live attenuated virus. Nature 221:744–747.

    Article  PubMed  CAS  Google Scholar 

  • Clifford P (1970) A review: on the epidemiology of nasopharyngeal carcinoma. Int J Cancer 5:287–309.

    Article  PubMed  CAS  Google Scholar 

  • Conway M, Morgan A, Mackett M (1989) Expression of Epstein-Barr virus antigen gp340/220 in mouse fibroblasts using a bovine papilloma virus vector. J Gen Virol 70:729–734.

    Article  PubMed  CAS  Google Scholar 

  • David EM, Morgan AJ (1988) Efficient purification of Epstein-Barr virus membrane antigen gp340 by fast protein liquid chromatography. J Immunol Methods 108:231–236.

    Article  PubMed  CAS  Google Scholar 

  • Deinhardt F, Jilg W (1986) Vaccines against hepatitis. Ann Inst Pasteur, Virol 137E:79–95.

    Article  Google Scholar 

  • De Schryver A, Klein G, Heweston J, Rocchi G, Henle W, Henle G, Moss DJ, Pope JH (1974) Comparison of EBV neutralization tests based on abortive infection or transformation of lymphoid cells and their relation to membrane reactive antibodies (anti MA). Int J Cancer 13:353–362.

    Article  PubMed  Google Scholar 

  • De-Thé G (1979) Demographic studies implicating the virus in the causation of Burkitt’s lymphoma; prospects for nasopharyngeal carcinoma. In Epstein MA, Achong BG (eds), The Epstein-Barr Virus, Berlin, Heidelberg, New York: Springer, pp. 417–473.

    Chapter  Google Scholar 

  • Doll R, Peto R (1976) Mortality in relation to smoking: 20 years’ observation on male British doctors. Brit Med J 2:1525–1536.

    Article  PubMed  CAS  Google Scholar 

  • Epstein MA (1976) Epstein-Barr virus — is it time to develop a vaccine program? J Nat Cancer Inst 56:697–700.

    PubMed  CAS  Google Scholar 

  • Epstein MA (1984) A prototype vaccine to prevent Epstein-Barr (EB) virus-associated tumours. Proc Roy Soc B Lond 221:1–20.

    Article  CAS  Google Scholar 

  • Epstein MA, Morgan AJ (1983) Clinical consequences of Epstein-Barr virus infection and possible control by an antiviral vaccine. Clin Exp Immunol 53:257–271.

    PubMed  CAS  Google Scholar 

  • Epstein MA, Morgan AJ, Finerty S, Randle BJ, Kirkwood JK (1985) Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature 318:287–289.

    Article  PubMed  CAS  Google Scholar 

  • Henle W, Henle G (1969) The relation between the Epstein-Barr virus and infectious mononucleosis, Burkitt’s lymphoma and cancer of the postnasal space. E African Med J 46:402–406.

    CAS  Google Scholar 

  • Hildreth JEK (1982) N-D-gluco-N-methylalanamide compounds, a new class of non-ionic detergents for membrane biochemistry. Biochem J 207:363–366.

    PubMed  CAS  Google Scholar 

  • Hummel M, Thorley-Lawson DA, Kieff E (1984) An Epstein-Barr virus DNA fragment encodes messages fo the two major envelope glycoproteins (gp350/300 and gp220/200). J Virol 49:413–417.

    PubMed  CAS  Google Scholar 

  • International Agency for Research on Cancer (1985) An intervention study to evaluate the effectiveness of hepatitis B vaccine for the prevention of hepatocellular carcinoma in a high risk population. IARC Working Paper 3/6:1–46.

    Google Scholar 

  • Kaaden OR, Dietzchold B (1974) Alterations of the immunological specificity of plasma membranes of cells infected with Marek’s disease and turkey herpes viruses. J Gen Virol 25:1–10.

    Article  PubMed  CAS  Google Scholar 

  • Kirkwood JK, Epstein MA, Terlecki AJ (1983) Factors influencing population growth of a colony of cotton-top tamarins. Lab Animals 17:45–41.

    Article  Google Scholar 

  • Kirkwood JK, Epstein MA, Terlecki AJ, Underwood SJ (1985) Rearing of a second generation of cotton-top tamarins (Saguinus oedipus oediupus) in captivity. Lab Animals 19:269–272.

    Article  CAS  Google Scholar 

  • Lanier A, Bender T, Talbot M, Wilmeth S, Tschopp C, Henle W, Henlw G, Ritter D, Terasaki P (1980) Nasopharyngeal carcinoma in Alaskan Eskimos, Indians and Aleuts: a review of cases and study of Epstein-Barr virus, HLA and environmental risk factors. Cancer 46:2100–2106.

    Article  PubMed  CAS  Google Scholar 

  • Lenoir GM, Bornkamm GW (1987) Burkitt’s lymphoma, a human cancer model for the study of the multistep development of cancer; proposal for a new scenario. In Klein G (ed) Advances in Viral Oncology Series Vol 7. New York, Raven Press, pp. 173–106.

    Google Scholar 

  • Lesnick F, Ross LJN (1975) Immunization against Marek’s disease using Marek’s disease virus-specific antigens free from infectious virus. Int J Cancer 16:153–163.

    Article  Google Scholar 

  • Lowe RS, Keller PM, Keech BJ, Davison AJ, Whang Y, Morgan AJ, Kieff E, Ellis RW (1987) Varicella-zoster virus as a live vector for the expression of foreign genes. Proc Natl Acad Sci USA 84:3896–3900.

    Article  PubMed  CAS  Google Scholar 

  • Mackett M, Arrand JR (1985) Recombinant vaccinia virus induces neutralizing antibodies in rabbits against Epstein-Barr virus membrane antigen gp340. EMBO J 3229-3234.

    Google Scholar 

  • Marek J (1907) Multiple Nervenentzündung (polyneuritis) bei Hühern. Deutsch Tierärztl Wschr 15:412–421.

    Google Scholar 

  • Miller G, Shope T, Coope D, Waters C, Pagano J, Bornkamm GW, Henle W (1977) Lymphoma in cotton-top marmosets after inoculation with Epstein-Barr virus: tumor incidence, histologic spectrum, antibody responses, demonstration of viral DNA, and characterization of viruses. J Exp Med 145:948–967.

    Article  PubMed  CAS  Google Scholar 

  • Morein B, Sundquist B, Höglund S, Dalsgaard K, Osterhaus A (1984) Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 308:457–460.

    Article  PubMed  CAS  Google Scholar 

  • Morein B, Lövgren K, Höglund S, Sundquist B (1987) The iscom: an immunostimulating complex. Immunol Today 8:333–338.

    Article  CAS  Google Scholar 

  • Morgan AJ, North JR, Epstein MA (1983) Purification and properties of the gp340 component of Epstein-Barr (EB) virus membrane antigen (MA) in an immunogenic form. J Med Virol 25:189–195.

    Article  Google Scholar 

  • Morgan AJ, Smith AR, Barker RN, Epstein MA (1984) A structural investigation of the Epstein-Barr (EB) virus membrane antigen glycoprotein, gp340. J Gen Virol 65:397–404.

    Article  PubMed  CAS  Google Scholar 

  • Morgan AJ, Finerty S, Lovgren K, Scullion FT, Morein B (1988a) Prevention of Epstein-Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulating complexes. J Gen Virol 69:2093–2096.

    Article  PubMed  CAS  Google Scholar 

  • Morgan AJ, Mackett M, Finerty S, Arrand J, Scullion F, Epstein MA (1988b) Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-incuded lymphomas. J Med Virol 25:189–195.

    Article  PubMed  CAS  Google Scholar 

  • Morgan AJ, Allison AC, Finerty S, Scullion FT, Byars NE, Epstein MA (1989) Validation of a first generation Epstein-Barr virus vaccine preparation suitable for human use. J Med Virol (in press).

    Google Scholar 

  • Moss DJ, Pope JH (1972) Assay of the infectivity of Epstein-Barr virus by transformation of human leucocytes in vitro. J Gen Virol 17:233–236.

    Article  PubMed  CAS  Google Scholar 

  • North JR, Morgan AJ, Thompson JL, Epstein MA (1982) Quantification of an EB virus-associated membrane antigen (MA) component. J Virol Methods 5:55–65.

    Article  PubMed  CAS  Google Scholar 

  • Okazaki W, Purchase HG, Burmester BR (1970) Protection against Marek’s disease by vaccination with a herpesvirus of turkeys. Avian Dis 14:413–429.

    Article  PubMed  CAS  Google Scholar 

  • Payne LN, Frazier JA, Powell PC (1976) Pathogenesis of Marek’s disease. In Richter GW, Epstein MA (eds) Internat Rev Exp Path, Vol. 16, New York, San Francisco, London; Academic Press, pp. 59–154.

    Google Scholar 

  • Provost PJ, Keller PM, Banker FS, Keech BJ, Klein HJ, Lowe RS, Morton DH, Phelps AH, McAleer WJ, Ellis RW (1987) Successful infection of the common marmoset (Callithrix jacchus) with human varicella-zoster virus. J Virol 61:2951–2955.

    PubMed  CAS  Google Scholar 

  • Purtilo DT, Sakamoto K, Barnabei V, Seeley J, Beechtold T, Rogers G, Yetz J, Harada S (1986) Epstein-Barr virus-induced diseases in boys with the X-linked lymphoproliferative syndrome (XLP). Am J Med 73:49–56.

    Article  Google Scholar 

  • Randle BJ, Epstein MA (1984) A highly sensitive enzyme-linked immunosorbent assay to quantitate antibodies to Epstein-Barr virus membrane antigen gp340. J Virol Methods 9:201–208.

    Article  PubMed  CAS  Google Scholar 

  • Schultz LD, Tanner J, Hofmann K, Emini E, Kieff E, Ellis RW (1987) Expression and analysis of EBV gp350 in yeast Saccharomyces cerevisiae. In Levine PH, Ablashi DV, Nonoyama M, Pearson GR, Glaser R (eds), Epstein-Barr Virus and Human Disease. Clifton, New Jersey, Humana Press, pp. 475–478.

    Chapter  Google Scholar 

  • Shanmugaratnam K (1971) Studies on the etiology of nasopharyngeal carcinoma. In Richter GW, Epstein MA (eds) Int Rev Exp Path, New York, London, Academic Press Inc, 10: pp. 361–413.

    Google Scholar 

  • Speijers G, Danse L, Bewary E, Strik J, Vos J (1988) Local reactions of the saponin Quil A and a Quil A-containing iscom measles vaccine after intramuscular injection of rats: a comparison with the effects of DPT-polio vaccine. Fundamental and Appl Toxicol 10:425–430.

    Article  CAS  Google Scholar 

  • Takahaski M, Otsuka T, Okuno Y, Asano Y, Yazaki T, Isomura S (1974) Live varicella vaccine used to prevent the spread of varicella in children in hospital. Lancet 2:1288–1290.

    Article  Google Scholar 

  • Whang Y, Silberklang M, Morgan A, Munshi S, Lenny AB, Ellis RW, Kieff E (1987) Expression of Epstein-Barr virus gp350-220 gene in rodent and primate cells. J Virol 61:1796–1807.

    PubMed  CAS  Google Scholar 

  • Whittle HC, Brown J, Marsh K, Greenwood BM, Seidelin P, Tighe H, Wedderburn L (1984) T cell control of B cells infected with EB virus is lost during P. falciparum malaria. Nature 312:229–250.

    Article  Google Scholar 

  • Zuckerman AJ (1985) Prevention of hepatocellular carcinoma by immunization against hepatitis B. In Epstein MA, Richter GW (eds) Int Rev Exp Path. Orlando, San Diego, New York, London, Toronto, Montreal, Sydney, Tokyo, Academic Press Inc, 25: pp. 59–81.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuffield Department of Clinical Medicine, University of Oxford John Radcliffe Hospital, Oxford, OX3 9DU, UK

    M. A. Epstein

Authors
  1. M. A. Epstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Irvine Medical Center, University of California, Orange, California, USA

    Luis M. de la Maza  & Ellena M. Peterson  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer Science+Business Media New York

About this chapter

Cite this chapter

Epstein, M.A. (1991). Plans for Human Trials of a Vaccine Against Epstein-Barr Virus Infection. In: de la Maza, L.M., Peterson, E.M. (eds) Medical Virology 9. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-5856-5_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4684-5856-5_11

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4684-5858-9

  • Online ISBN: 978-1-4684-5856-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation